Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHAZOLAMIDE vs ACETAZOLAMIDE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
FDA: Adjunctive treatment of open-angle glaucoma or secondary glaucoma; preoperative treatment of acute angle-closure glaucoma.,Off-label: Management of idiopathic intracranial hypertension (pseudotumor cerebri); metabolic alkalosis; acute mountain sickness.
Treatment of open-angle glaucoma and secondary glaucoma,Preoperative and perioperative reduction of intraocular pressure in acute angle-closure glaucoma,Treatment of edema due to congestive heart failure when other diuretics are ineffective,Adjunctive treatment of epilepsy (centrencephalic epilepsies, absence seizures),Prophylaxis and treatment of acute mountain sickness
Oral: 50-100 mg two to three times daily.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Hepatic metabolism via CYP3A4; metabolites include N-demethylated and S-oxidized products.
Acetazolamide is minimally metabolized in the liver, with the majority of the drug excreted unchanged in the urine. The primary metabolic pathway involves oxidation of the thiadiazole ring, but this is a minor route. The drug is not extensively biotransformed; hepatic metabolism accounts for less than 10% of elimination.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
~95% bound to plasma proteins (primarily albumin)
70-90% (mainly carbonic anhydrase in RBCs; low affinity for albumin).
0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid
Approximately 0.2-0.3 L/kg; mainly confined to extracellular fluid and highly perfused tissues.
Oral: ~90% (well absorbed); IM: not typically used; IV: 100%
Oral: ~90-100% (rapidly absorbed; food may delay). Intramuscular: not recommended (acidic p H).
GFR 10-50 m L/min: Administer every 12 hours; GFR <10 m L/min: Not recommended.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: avoid or use with extreme caution.
No specific guidelines; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to 24-48 hours. Child-Pugh C: avoid use.
Oral: 5-10 mg/kg/day divided every 6-8 hours; maximum 30 mg/kg/day.
For edema: 5 mg/kg IV or IM once daily. For glaucoma: 10-15 mg/kg/day IV or IM in divided doses every 6-8 hours.
Initiate at low end of dosing range due to age-related renal function decline; monitor electrolytes and renal function.
Initiate at lowest adult dose; monitor renal function and electrolytes; adjust based on creatinine clearance.
None.
None
Sulfonamide hypersensitivity reactions; metabolic acidosis; electrolyte disturbances (hypokalemia); drowsiness and confusion; potentiation of acidosis in renal impairment; risk of nephrolithiasis; caution with concomitant use of high-dose aspirin (risk of toxicity).
Use with caution in patients with hepatic cirrhosis, as acetazolamide can precipitate hepatic encephalopathy due to increased ammonia levels,May cause metabolic acidosis, which can be severe with prolonged use; monitor serum electrolytes and bicarbonate levels,Can precipitate renal calculi due to decreased urinary citrate excretion; ensure adequate hydration,May cause drowsiness, confusion, or ataxia; caution when operating machinery or driving,Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease, as metabolic acidosis may worsen respiratory function,Monitor for signs of hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis,May cause hematologic reactions such as agranulocytosis, aplastic anemia, and thrombocytopenia; monitor blood counts
Hyponatremia or hypokalemia; severe renal or hepatic impairment; adrenal insufficiency; hypersensitivity to sulfonamides or thiazide diuretics; concurrent use with high-dose aspirin.
Known hypersensitivity to acetazolamide or any sulfonamide-derivative (although cross-reactivity may not occur, caution is advised),Severe hepatic insufficiency or cirrhosis with risk of hepatic encephalopathy,Severe renal impairment (e.g., anuria, glomerular filtration rate <10 m L/min),Metabolic acidosis,Hyponatremia or hypokalemia,Concurrent use with high-dose aspirin (risk of metabolic acidosis and increased salicylate toxicity)
No specific food interactions. Maintain adequate hydration. Avoid excessive intake of sodium bicarbonate or antacids containing bicarbonate.
No specific food interactions reported. However, high-sodium foods may counteract the diuretic effect. Maintain adequate fluid intake to prevent kidney stones. Avoid large amounts of caffeine as it may increase diuresis and electrolyte loss.
First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: Risk of fetal acidosis and electrolyte disturbances due to carbonic anhydrase inhibition. Avoid if possible.
Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human data limited but suggests potential teratogenicity. Second and third trimesters: may cause fetal metabolic acidosis, electrolyte disturbances, and growth restriction due to carbonic anhydrase inhibition.
Methazolamide is excreted into breast milk; M/P ratio not established. Potential for metabolic acidosis or sulfonamide-related adverse effects in nursing infant. Use only if benefit outweighs risk; consider alternative agents.
Acetazolamide is excreted into breast milk in low amounts. M/P ratio is approximately 0.25. Infant exposure is minimal but may cause metabolic acidosis or diuresis. Caution is advised; monitor infant for signs of acidosis or dehydration.
No pharmacokinetic studies in pregnancy; increased glomerular filtration rate may reduce serum levels. Empirical dose adjustment not recommended; monitor clinical effect and adjust as needed.
Dose adjustments may be necessary due to increased renal clearance and volume of distribution in pregnancy. Monitor therapeutic effect and adverse reactions; consider starting at lower doses and titrating based on response. No standardized guidelines exist; individualize therapy.
Methazolamide is a carbonic anhydrase inhibitor used for glaucoma. Monitor serum electrolytes, especially potassium, as hypokalemia is common. Contraindicated in patients with hepatic cirrhosis due to risk of hepatic encephalopathy. Avoid in patients with adrenal insufficiency. Adjust dose in renal impairment. Use with caution in patients with pulmonary obstruction or emphysema as it can cause metabolic acidosis.
Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness prophylaxis, glaucoma, and as a diuretic. Monitor for metabolic acidosis, especially in elderly or renal impairment. Can cause hypokalemia; check serum potassium. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. May cause paresthesias, especially in hands and feet, which are harmless but can be distressing.
Take this medication exactly as prescribed, usually twice a day.,You may experience tingling in the fingers or toes, which is common and usually harmless.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of infection, easy bruising, or bleeding.,Do not drive or operate heavy machinery until you know how this medication affects you.,This medication may cause sensitivity to sunlight; use sunscreen and protective clothing.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double dose.
Take with food to reduce gastrointestinal upset.,May cause tingling in fingers, toes, or face; this is usually temporary and not harmful.,Drink plenty of fluids unless otherwise instructed to prevent kidney stones.,Avoid alcohol as it may increase side effects like dizziness.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report any signs of unusual bleeding, bruising, or signs of infection to your healthcare provider.,Take exactly as prescribed; do not stop suddenly without consulting your doctor.,If used for altitude sickness, start 24-48 hours before ascent and continue for 48 hours at high altitude.
"The combination of Triamterene, a potassium-sparing diuretic that inhibits epithelial sodium channels in the distal nephron, with Methazolamide, a carbonic anhydrase inhibitor that reduces renal bicarbonate reabsorption, can lead to severe hyperkalemia and metabolic acidosis due to additive effects on renal electrolyte handling. Both drugs impair renal potassium secretion, while Methazolamide-induced metabolic acidosis further exacerbates hyperkalemia by shifting potassium extracellularly. This synergistic disruption of acid-base balance and potassium homeostasis significantly increases the risk of life-threatening cardiac arrhythmias and neurological impairment."
"Carteolol, a non-selective beta-blocker, can blunt the compensatory sympathetic response to metabolic acidosis induced by methazolamide, a carbonic anhydrase inhibitor. This can lead to excessive bradycardia, hypotension, and potentially precipitate heart failure. The additive effects on lowering intraocular pressure may also be affected."
"Phentermine, a sympathomimetic amine, may competitively inhibit the renal tubular secretion of methazolamide, a carbonic anhydrase inhibitor primarily eliminated via active tubular secretion. This can lead to reduced clearance and increased systemic exposure of methazolamide, potentially elevating its serum levels and prolonging its therapeutic and adverse effects such as metabolic acidosis, paresthesias, and electrolyte imbalances. Clinical outcomes may include increased risk of methazolamide toxicity, particularly in patients with renal impairment, and enhanced diuretic or ocular hypotensive effects."
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHAZOLAMIDE vs ACETAZOLAMIDE SODIUM, answered by our medical review team.
METHAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.. ACETAZOLAMIDE SODIUM is a Carbonic Anhydrase Inhibitor that works by Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHAZOLAMIDE and ACETAZOLAMIDE SODIUM depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHAZOLAMIDE is: Oral: 50-100 mg two to three times daily.. The standard adult dose of ACETAZOLAMIDE SODIUM is: Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METHAZOLAMIDE and ACETAZOLAMIDE SODIUM. The combination of Methazolamide and Acetazolamide, both carbonic anhydrase inhibitors, leads to additive pharmacological effects, resulting in an increased risk of metabolic acidosis, electrolyte imbalances (particularly hypokalemia), and central nervous system depression. This interaction can precipitate severe symptoms such as confusion, lethargy, and respiratory compensation failure, especially in patients with renal impairment or concurrent diuretic use. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METHAZOLAMIDE is classified as Category C. First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: R. ACETAZOLAMIDE SODIUM is classified as Category C. Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.